Facilities & Capabilities

  • 5 distinct GMP facilities in Atlantic Canada 
    • Headquarters and 4 complex chemistry facilities in Charlottetown, Prince Edward Island
    •  Biologics manufacturing in Windsor, Nova Scotia
  • +25,000 m²  manufacturing facility space
  • 118,000 L of chemical reactor space (20 L to 18,000 L)
  • 64,000 L of fermentation bioreactor capacity (30 L to 17,000 L)
  • Various development and GMP manufacturing areas providing different types of capabilities, including:
    • Class 100,000 (ISO 8/ Grade D) and 10,000 (ISO 7/ Grade C) controlled suites
    • Highly Potent API Band 3 and 4 containment suites
    • Commercial synthetic API manufacturing
    • Commercial biologic drug substance production
    • Full biologics development and characterization
    • Multi-Reactor System and scale down high throughput setup 
    • Continuous processing/flow chemistry equipment
    • Analytical development and 24/7 quality control
  • Multiple qualified GMP storage areas (-80°C to 2-8°C) for raw materials, cell lines, and drug substances


Synthetic Small Molecules

Fermented Small Molecules

Highly Potent APIs



Regulatory Inspection History
Research & Development

17 Hillstrom Ave., PE

  • Lab
  • Pilot
  • Non-GMP Commercial scale
  • Lab
  • Pilot
  • Lab
  • Pilot
  • Commercial
  • Lab
  • Pilot, Non-GMP


11 Aviation Ave., PE

  • Pilot, GMP, Classified
  • Commercial GMP
  • Large-scale Commercial GMP
  • Pilot GMP
  • Commercial GMP
  • Lab
  • Pilot
  • Commercial
  • Commercial GMP

New API Facility

11 Aviation Ave., PE

  • Lab GMP
  • Large-scale Commercial GMP
Large Scale Biomanufacturing Facility

24 Ivey Lane, NS

  • Lab
  • Pilot
  • Clinical
  • Large-scale commercial
Dedicated Facility

29 McCarville St., PE

Dedicated Natural Extraction

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors